The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Research Report 2024
Synopsis
Exocrine pancreatic insufficiency (EPI) refers to the condition wherein the body is unable to produce sufficient amounts of exocrine pancreatic enzymes, thus leading to difficulties in digesting food properly. The condition occurs due to the lack of sufficient enzymes necessary for fat digestion, amylases for starch digestion, and proteases for protein digestion.
The global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market was valued at US$ 3505 million in 2023 and is anticipated to reach US$ 4782.2 million by 2030, witnessing a CAGR of 4.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics.
Report Scope
The Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Allergan
Nordmark Arzneimittel
Digestive Care
Janssen Pharmaceuticals
Cilian
Anthera Pharmaceuticals
AzurRx Biopharma
Segment by Type
Therapeutics
Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)
Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Exocrine pancreatic insufficiency (EPI) refers to the condition wherein the body is unable to produce sufficient amounts of exocrine pancreatic enzymes, thus leading to difficulties in digesting food properly. The condition occurs due to the lack of sufficient enzymes necessary for fat digestion, amylases for starch digestion, and proteases for protein digestion.
The global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market was valued at US$ 3505 million in 2023 and is anticipated to reach US$ 4782.2 million by 2030, witnessing a CAGR of 4.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics.
Report Scope
The Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Allergan
Nordmark Arzneimittel
Digestive Care
Janssen Pharmaceuticals
Cilian
Anthera Pharmaceuticals
AzurRx Biopharma
Segment by Type
Therapeutics
Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)
Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Therapeutics
1.2.3 Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)
1.3 Market by Application
1.3.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Perspective (2019-2030)
2.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Growth Trends by Region
2.2.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Dynamics
2.3.1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Industry Trends
2.3.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Drivers
2.3.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Challenges
2.3.4 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players by Revenue
3.1.1 Global Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue
3.4 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Concentration Ratio
3.4.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in 2023
3.5 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Key Players Head office and Area Served
3.6 Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Solution and Service
3.7 Date of Enter into Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Breakdown Data by Type
4.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Forecasted Market Size by Type (2025-2030)
5 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Breakdown Data by Application
5.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2019-2030)
6.2 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2019-2024)
6.4 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2019-2030)
7.2 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2019-2024)
7.4 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2019-2030)
9.2 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.1.4 AbbVie Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 Allergan
11.2.1 Allergan Company Detail
11.2.2 Allergan Business Overview
11.2.3 Allergan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.2.4 Allergan Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2019-2024)
11.2.5 Allergan Recent Development
11.3 Nordmark Arzneimittel
11.3.1 Nordmark Arzneimittel Company Detail
11.3.2 Nordmark Arzneimittel Business Overview
11.3.3 Nordmark Arzneimittel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.3.4 Nordmark Arzneimittel Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2019-2024)
11.3.5 Nordmark Arzneimittel Recent Development
11.4 Digestive Care
11.4.1 Digestive Care Company Detail
11.4.2 Digestive Care Business Overview
11.4.3 Digestive Care Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.4.4 Digestive Care Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2019-2024)
11.4.5 Digestive Care Recent Development
11.5 Janssen Pharmaceuticals
11.5.1 Janssen Pharmaceuticals Company Detail
11.5.2 Janssen Pharmaceuticals Business Overview
11.5.3 Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.5.4 Janssen Pharmaceuticals Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2019-2024)
11.5.5 Janssen Pharmaceuticals Recent Development
11.6 Cilian
11.6.1 Cilian Company Detail
11.6.2 Cilian Business Overview
11.6.3 Cilian Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.6.4 Cilian Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2019-2024)
11.6.5 Cilian Recent Development
11.7 Anthera Pharmaceuticals
11.7.1 Anthera Pharmaceuticals Company Detail
11.7.2 Anthera Pharmaceuticals Business Overview
11.7.3 Anthera Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.7.4 Anthera Pharmaceuticals Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2019-2024)
11.7.5 Anthera Pharmaceuticals Recent Development
11.8 AzurRx Biopharma
11.8.1 AzurRx Biopharma Company Detail
11.8.2 AzurRx Biopharma Business Overview
11.8.3 AzurRx Biopharma Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
11.8.4 AzurRx Biopharma Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2019-2024)
11.8.5 AzurRx Biopharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
